Oncology News | pharmaphorum

News

Merck & Co axes Keytruda lung cancer niche amid FDA crackdow...

Merck & Co has voluntarily withdrawn its Keytruda immunotherapy from a lung cancer niche in the US, amid a crackdown by the FDA on drugs approved without the required post-marketing dat

News

Merck KGaA offloads failed MEK programme to startup Day One

US biotech Day One has taken ownership of a cancer drug that has been languishing in Merck KGaA’s pipeline for years, in the hope of giving it a new lease of life.

News

FDA to quickly review Incyte's Jakafi in chronic GVHD

The FDA is to begin a fast review of Incyte’s Jakafi (ruxolitinib) for patients with chronic graft-versus-host disease (GVHD), which cannot be treated with steroids.

News

DNA strand and Cancer Cell Oncology Research Concept 3D rendering

Limited access to cancer biomarker testing in Europe, report...

There is limited access to biomarker testing for cancer in Europe, despite the huge potential of the technology to improve outcomes, according to a new report.

News

Sanofi's immunotherapy Libtayo gets FDA approval in first li...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients.

News

MHRA approves Seagen’s oral HER2 drug Tukysa

The UK drugs regulator has approved Seagen’s Tukysa as a third-line treatment for HER2-positive breast cancer, shortly after it was given a green light by the European Commission.

Merck & Co axes Keytruda lung cancer niche amid FDA crackdow...

Merck KGaA offloads failed MEK programme to startup Day One

FDA to quickly review Incyte's Jakafi in chronic GVHD

Limited access to cancer biomarker testing in Europe, report...

Sanofi's immunotherapy Libtayo gets FDA approval in first li...

MHRA approves Seagen’s oral HER2 drug Tukysa

Third Rock in $2bn drug-hunting pact with China's Funnel

Securing your ROI: Turning post-acquisition integration into...

News

Editor's Picks